Recro Pharma (REPH) Misses Q3 EPS by 10c

Recro Pharma (NASDAQ: REPH) reported Q3 EPS of ($0.61), $0.10 worse than the analyst estimate of ($0.51).

For earnings history and earnings-related data on Recro Pharma (REPH) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• The free USDA tool that tracks egg prices at $0.62/dozen before your data vendor does
• Rexford Industrial agrees to sell $1.2B portfolio to EQT Real Estate